OpGen, Inc. announced that four new members have joined its Clinical Advisory Board (CAB). Joining the board are Debra A. Goff, Pharm.D., FCCP, Dag Harmsen, M.D., Stefan Riedel, M.D. Ph.D., D(ABMM), FCAP, and Morton Sommer, Ph.D. Returning CAB members include Attila Lorincz, Ph.D. and James W. Snyder, Ph.D., D(ABMM), FAAM. Dr. Goff, a founding member of the school's Antimicrobial Stewardship Program at the Department of Pharmacy, is actively involved in developing strategies to improve patient outcomes and control the escalating rate of antimicrobial resistance.

During the past 20 years, Dr. Harmsen has been best known for delivering popular applied microbiology informatics solutions, such as spa-typing for MRSA with a global nomenclature SpaServer, or the MIRU-VNTRplus service for m. tuberculosis typing. Dr. Lorincz is Director of the Molecular Epidemiology Laboratory at the Wolfson Institute of Preventive Medicine at the Queen Mary University of London. Dr. Riedel is Associate Medical Director of the Clinical Microbiology Laboratories at Beth Israel Deaconess Medical Center in Boston and Associate Professor, Pathology at the Harvard Medical School.

Dr. Snyder is Medical Director of the Clinical Microbiology and Molecular Diagnostics laboratory at the University of Louisville Hospital, and is professor of pathology and laboratory medicine at the University's School of Medicine and Dr. Sommer is Professor and Associate Scientific Director at the Novo Nordisk Foundation Center for Biosustainability at the Technical University of Denmark.